Current heart failure reports · 2026
Beyond Continuous-Flow: The Next Wave of Fully Implantable LVADs and Total Artificial Hearts.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hada Tasuku, Baranowska Julia, Takeda Koji, Sayer Gabriel T, Uriel Nir
Аннотация
PURPOSE OF REVIEW: Ventricular assist devices (VADs) have evolved from a bridge-to-transplantation strategy into a cornerstone of long-term advanced heart failure management. While continuous-flow technology has dramatically improved survival and device reliability, the paradigm shift toward extended mechanical circulatory support has exposed critical unresolved challenges. This review examines current limitations and four transformative technological directions shaping the next generation of VAD therapy.
RECENT FINDINGS: Four key areas are driving innovation in the field. First, growing evidence linking prolonged non-pulsatile hemodynamics to vascular dysfunction and hemorrhagic complications has renewed interest in miniaturized pulsatile devices, with multiple engineering approaches under active investigation. Second, the development of physiologically responsive "smart pump" technology represents a major advance, enabling dynamic modulation of pump output in response to patient hemodynamic demands. Third, transcutaneous energy transfer (TET) systems combined with advanced battery technologies are progressing toward fully implantable designs that would eliminate driveline-related infections, a persistent and clinically significant complication of current-generation devices. Fourth, total artificial heart (TAH) development continues to advance, with both pulsatile and continuous-flow platforms incorporating TET technology to address biventricular failure. Despite ongoing challenges in balancing miniaturization, durability, and biocompatibility, these four innovations collectively hold promise for transforming mechanical circulatory support into a viable long-term therapeutic option, improving both survival and quality of life for a broader population of patients with advanced heart failure.
RECENT FINDINGS: Four key areas are driving innovation in the field. First, growing evidence linking prolonged non-pulsatile hemodynamics to vascular dysfunction and hemorrhagic complications has renewed interest in miniaturized pulsatile devices, with multiple engineering approaches under active investigation. Second, the development of physiologically responsive "smart pump" technology represents a major advance, enabling dynamic modulation of pump output in response to patient hemodynamic demands. Third, transcutaneous energy transfer (TET) systems combined with advanced battery technologies are progressing toward fully implantable designs that would eliminate driveline-related infections, a persistent and clinically significant complication of current-generation devices. Fourth, total artificial heart (TAH) development continues to advance, with both pulsatile and continuous-flow platforms incorporating TET technology to address biventricular failure. Despite ongoing challenges in balancing miniaturization, durability, and biocompatibility, these four innovations collectively hold promise for transforming mechanical circulatory support into a viable long-term therapeutic option, improving both survival and quality of life for a broader population of patients with advanced heart failure.